FDA panel weighs regulation of unproven peptide therapies
#FDA #PeptideRegulationThe FDA convenes experts this week to decide if compounding pharmacies can produce popular but unproven injectable peptides like TB-500 and BPC-157. Advocates cite grey market risks, while scientists warn of sparse human evidence and potential safety dangers. read more
There are no other PeptideRegulation articles to read at this time.
Check out some of these other topics...